Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1

Yayla, Uğur; Sevik, Mehmet Orkun; Karabaş, Veysel Levent; Şahin, Özlem; Özkaya, Abdullah; Yenerel, Nursal Melda; Açıkalın Öncel, Banu; Kaplan, Fatih Bilgehan; Önder Tokuç, Ecem; Kanar, Hatice Selen; Kutlutürk Karagöz, Işıl; Başaran Emengen, Ece; Demirciler Sönmez, Ayşe; Aykut, Aslan; Limon, Utku

doi:10.4274/tjo.galenos.2023.56249

Cited by 5 publications

(2 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until recently, visual acuity and central macular thickness were set as reproducible and robust endpoints in virtually all prospective comparative anti-VEGF studies by the national health authorities [ 35 ]. However, the clinical study outcomes have regularly been found to be superior to real life, where case selection criteria of RCTs cannot be applied [ 36 , 37 , 38 , 39 ]. Moreover, visual gains and change in CRT are comparable between the marketed drugs and are thus not able to differentiate between the different drugs on the market [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab

Garweg,

Steinhauer

2024

JCM

View full text Add to dashboard Cite

Background: Treatment cessation due to a dry retina has not been systematically addressed in diabetic macular edema (DME). In three out of four patients receiving 6 mg of brolucizumab in the KITE study, treatment was terminated after the study ended. Methods: The KITE study was a double-masked, multicenter, active-controlled, randomized trial (NCT 03481660) in DME patients. Per protocol, patients received five loading injections of Brolucizumab at 6-week intervals, with the option to adjust to 8 weeks in case of disease activity or to extend in the second year to a maximum of 16 weeks in the absence of retinal fluid. Results: After two years, one patient required eight weekly injections, while three patients reached a maximal treatment interval of 16 weeks. The severity of diabetic retinopathy improved in all patients with no dye leakage according to fluorescein angiography (FA) and no retinal fluid according to OCT in three patients. Treatment was paused in these three patients for >36 months, while the fourth patient required continuous treatment at 5-week intervals after switching to other licensed anti-VEGF agents. Conclusions: The adoption of treatment according to individual needs, including considering treatment cessation, may contribute to improved treatment adherence in many patients and be more frequently possible than expected.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab

Garweg,

Steinhauer

2024

JCM

View full text Add to dashboard Cite

show abstract

“…However, studies with longer follow-up periods may reveal subtle differences in efficacy of these anti-VEGF agents. Table 4 summarizes the outcomes of studies published over the last 12 years pertaining to anti-VEGF DME management [ 12 - 16 , 28 , 36 - 68 ] .…”

Section: Discussionmentioning

confidence: 99%

Aflibercept or ranibizumab for diabetic macular edema

Abdelhalim Ali Ali,

Saied Hegazy,

Othman Abdelkhalek Elsayed

et al. 2024

Med Hypothesis Discov Innov Ophthalmol

View full text Add to dashboard Cite

Background: Vascular endothelial growth factor (VEGF) is the primary substance involved in retinal barrier breach. VEGF overexpression may cause diabetic macular edema (DME). Laser photocoagulation of the macula is the standard treatment for DME; however, recently, intravitreal anti-VEGF injections have surpassed laser treatment. Our aim was to evaluate the efficacy of intravitreal injections of aflibercept or ranibizumab for managing treatment-naive DME. Methods: This single-center, retrospective, interventional, comparative study included eyes with visual impairment due to treatment-naive DME that underwent intravitreal injection of either aflibercept 2 mg/0.05 mL or ranibizumab 0.5 mg/0.05 mL at Al-Azhar University Hospitals, Egypt between March 2023 and January 2024. Demographic data and full ophthalmological examination results at baseline and 1, 3, and 6 months post-injection were collected, including the best-corrected distance visual acuity (BCDVA) in logarithm of the minimum angle of resolution (logMAR) notation, slit-lamp biomicroscopy, dilated fundoscopy, and central subfield thickness (CST) measured using spectral-domain optical coherence tomography. Results: Overall, the 96 eyes of 96 patients with a median (interquartile range [IQR]) age of 57 (10) (range: 20–74) years and a male-to-female ratio of 1:2.7 were allocated to one of two groups with comparable age, sex, diabetes mellitus duration, and presence of other comorbidities (all P >0.05). There was no statistically significant difference in baseline diabetic retinopathy status or DME type between groups (both P >0.05). In both groups, the median (IQR) BCDVA significantly improved from 0.7 (0.8) logMAR at baseline to 0.4 (0.1) logMAR at 6 months post-injection (both P = 0.001), with no statistically significant difference between groups at all follow-up visits (all P >0.05). The median (IQR) CST significantly decreased in the aflibercept group from 347 (166) µm at baseline to 180 (233) µm at 6 months post-injection, and it decreased in the ranibizumab group from 360 (180) µm at baseline to 190 (224) µm at 6 months post-injection (both P = 0.001), with no statistically significant differences between groups at all follow-up visits (all P >0.05). No serious adverse effects were documented in either group. Conclusions: Ranibizumab and aflibercept were equally effective in achieving the desired anatomical and functional results in patients with treatment-naive DME in short-term follow-up without significant differences in injection counts between both drugs. Larger prospective, randomized, double-blinded trials with longer follow-up periods are needed to confirm our preliminary results.

show abstract

Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10

Bozkurt,

Kaplan,

Önder Tokuç

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1

Cited by 5 publications

References 68 publications

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab

Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab

Aflibercept or ranibizumab for diabetic macular edema

Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10

Contact Info

Product

Resources

About